Pharma Line srl

pharmaline.org

Pharma Line srl is a pharmaceutical company focused on high quality and innovative solutions. We are engaged in the research, development and marketing of original formulations supported by strong and rigorous scientific literature. The values inspiring all of our work are excellence and innovation. We work to improve patients’ quality of life and respond to their potential needs.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights, PHARMACY MARKET

HARROW INTRODUCES NEXT-GEN COMPOUNDED ATROPINE FORMULATIONS

Harrow | February 16, 2023

news image

On February 15, 2023, Harrow, a renowned pharmaceutical firm specializing in eyecare in the United States, announced the launch of its next-generation, patent-pending compounded Atropine formulations. These formulations are now accessible through ImprimisRx, a mail-order pharmacy subsidiary wholly owned by Harrow. The following are the key features of ImprimisRx's next-generation Atropine formulations Thoroughly validated analytical tests are conducted to...

Read More

PREMIER INC. SUPPORTS FDA, DEA REFORMS AND REGULATORY WAIVERS TO COUNTER DRUG SHORTAGES

Premier Inc. | July 24, 2020

news image

Premier Inc. today provided the U.S. Food and Drug Administration (FDA) and the U.S. Drug Enforcement Administration (DEA) with a list of reforms and regulatory waivers that the company believes should be extended beyond the COVID-19 pandemic and made permanent thereafter in order to prevent drug shortages. “During the height of the COVID-19 pandemic, we saw demand for many common pharmaceuticals surge by an average of more than 150 percent,” said Blair Childs, Premier...

Read More

NOVARTIS COLLABORATES WITH DNDI FOR VISCERAL LEISHMANIASIS DRUG

Pharmaceutical Technology | February 25, 2020

news image

Swiss pharma giant Novartis and non-profit research and development organisation Drugs for Neglected Diseases initiative (DNDi) have signed a collaboration and license agreement to jointly develop LXE408 for visceral leishmaniasis. LXE408 is an oral treatment for this parasitic disease, which is transmitted by the bite of a sand fly, and can be life-threatening if left untreated. The drug was initially discovered by Novartis with the financial backing of the Wellcome Trust. DNDi executive direct...

Read More

Business Insights, PHARMACY MARKET

VERO BIOTECH ANNOUNCES FDA APPROVAL FOR ITS SECOND-GEN GENOSYL DS

VERO Biotech | February 03, 2023

news image

On February 2, 2023, VERO Biotech Inc., a commercial-stage biotechnology company focused on neonatal intensive care and the acute care hospital community, announced that FDA has approved its innovative second-generation GENOSYL® Inhaled Nitric Oxide (iNO) delivery system for use in the operating room with rebreathing anesthesia. The second generation GENOSYL® DS is now the first and only iNO delivery device approved for use in both rebreathing and non-rebreathing anesthesia procedu...

Read More
news image

Business Insights, PHARMACY MARKET

HARROW INTRODUCES NEXT-GEN COMPOUNDED ATROPINE FORMULATIONS

Harrow | February 16, 2023

On February 15, 2023, Harrow, a renowned pharmaceutical firm specializing in eyecare in the United States, announced the launch of its next-generation, patent-pending compounded Atropine formulations. These formulations are now accessible through ImprimisRx, a mail-order pharmacy subsidiary wholly owned by Harrow. The following are the key features of ImprimisRx's next-generation Atropine formulations Thoroughly validated analytical tests are conducted to...

Read More
news image

PREMIER INC. SUPPORTS FDA, DEA REFORMS AND REGULATORY WAIVERS TO COUNTER DRUG SHORTAGES

Premier Inc. | July 24, 2020

Premier Inc. today provided the U.S. Food and Drug Administration (FDA) and the U.S. Drug Enforcement Administration (DEA) with a list of reforms and regulatory waivers that the company believes should be extended beyond the COVID-19 pandemic and made permanent thereafter in order to prevent drug shortages. “During the height of the COVID-19 pandemic, we saw demand for many common pharmaceuticals surge by an average of more than 150 percent,” said Blair Childs, Premier...

Read More
news image

NOVARTIS COLLABORATES WITH DNDI FOR VISCERAL LEISHMANIASIS DRUG

Pharmaceutical Technology | February 25, 2020

Swiss pharma giant Novartis and non-profit research and development organisation Drugs for Neglected Diseases initiative (DNDi) have signed a collaboration and license agreement to jointly develop LXE408 for visceral leishmaniasis. LXE408 is an oral treatment for this parasitic disease, which is transmitted by the bite of a sand fly, and can be life-threatening if left untreated. The drug was initially discovered by Novartis with the financial backing of the Wellcome Trust. DNDi executive direct...

Read More
news image

Business Insights, PHARMACY MARKET

VERO BIOTECH ANNOUNCES FDA APPROVAL FOR ITS SECOND-GEN GENOSYL DS

VERO Biotech | February 03, 2023

On February 2, 2023, VERO Biotech Inc., a commercial-stage biotechnology company focused on neonatal intensive care and the acute care hospital community, announced that FDA has approved its innovative second-generation GENOSYL® Inhaled Nitric Oxide (iNO) delivery system for use in the operating room with rebreathing anesthesia. The second generation GENOSYL® DS is now the first and only iNO delivery device approved for use in both rebreathing and non-rebreathing anesthesia procedu...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us